0001493152-21-020130.txt : 20210816 0001493152-21-020130.hdr.sgml : 20210816 20210816160154 ACCESSION NUMBER: 0001493152-21-020130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210816 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 211177714 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 8-K 1 form8-k.htm
0001349929 false 0001349929 2021-08-16 2021-08-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 16, 2021

 

VYANT BIO, INC.

(Exact Name of Company as Specified in its Charter)

 

Delaware   001-35817   04-3462475

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code (201) 479-8126

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VYNT   The Nasdaq Capital Market

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 16, 2021, Vyant Bio, Inc. (the “Registrant”) issued a press release regarding financial results for the fiscal quarter ended June 30, 2021. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Forward-Looking Statements

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations or transactions. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

As described above, the following exhibits are furnished as part of this report:

 

Exhibit 99.1 - Press release, dated August 16, 2021.

Exhibit 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VYANT BIO, INC.
       
    By: /s/ John A. Roberts
    Name: John A. Roberts
    Title: President and Chief Executive Officer
       
Date: August 16, 2021    

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates

 

Strategic Highlights

 

●Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States Patent and Trademark Office (USPTO). The patent covers the use of spheroids and organoids for drug discovery.

 

●Entered into a strategic collaboration with Ordaos Bio and Cellaria, Inc. to execute an integrated model for rapid iteration of therapeutic design using artificial intelligence (“AI”) and human-derived in vitro ‘avatar clinical trials’ to enable the design, development, and testing of potential therapeutics on targeted patient populations, during preclinical discovery with a primary focus in oncology.

 

●Completed a large primary screening of AI-generated novel compounds for Rett Syndrome yielding promising results, including a first round of hit expansion screening across two novel targets.

 

●Elevated our syngeneic bladder instillation model into toxicology screening, which will be performed in vivoPharm’s animal models.

 

●Progressed internal programs that apply Vyant Bio’s expertise with human-derived cell-based organoids to explore neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease.

 

●Commenced the development of AI-based molecule and biologic creation for in-vitro testing through in-silico structure-function prediction.

 

●Cash position at June 30, 2021 was $26.5 million.

 

CHERRY HILL, N.J., August 16, 2021 (GLOBE NEWSWIRE) – Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio reports its Second Quarter 2021 strategic and business updates in a conference call scheduled for 4:30 p.m. ET.

 

“We have achieved a tremendous amount of momentum in the first 90 days since launching the Vyant Bio brand and completing the merger we announced at the end of March 2021. Vyant Bio is committed to transforming the way drugs are discovered by quickly adapting to exciting new technologies and combining capabilities in ways that leverage their strengths,” stated Jay Roberts, CEO of Vyant Bio. “Our internal teams of scientists, data scientists and engineers, coupled with the capabilities of select strategic partners that are now integrated into our platform, allow us all to work together to design and develop superior therapeutics and position us to build a robust pipeline of novel therapeutics targeting degenerative and developmental neurological disorders and cancers with high unmet needs.”

 

   
 

 

Vyant Bio’s drug discovery platform uses both human-induced pluripotent stem cell-derived (hiPSC) and primary human cell organoids as proprietary disease models combined with analysis of human genetics and the use of machine learning algorithms for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. Vyant Bio’s drug discovery platform is intended to overcome the shortcomings of traditional drug discovery efforts that rely more heavily on insights from animal models to identify targets and to develop therapies intended for human disease. The Company is currently focused on the specific utility for the identification of targets and therapies in CNS and Oncology.

 

The Company filed its quarterly report for the Second Quarter 2021 on Form 10-Q today with the Securities and Exchange Commission. Please refer to our Form 10-Q for more detailed information with respect to our financial results for the three and six months ended June 30, 2021.

 

SECOND QUARTER 2021 FINANCIAL RESULTS1

 

As StemoniX, Inc. was deemed to have acquired Cancer Genetics, Inc. for accounting purposes and the Merger closed on March 30, 2021, the Company’s Second Quarter 2021 financial results include the post-merger results of the combined companies, now known as Vyant Bio. The analysis below excludes the Second Quarter 2020 results as they are based solely on StemoniX’s historical stand-alone operations and therefore do not reflect the post-merger enterprise.

 

Cash and cash equivalents totaled $26.5 million as of June 30, 2021.

 

Total revenues were $1.9 million for the three months ended June 30, 2021. Cost of goods sold – service aggregated to $1.0 million for the three months ended June 30, 2021 resulting in a cost of goods sold of 56% of service revenues. Cost of goods sold – product aggregated to $345 thousand for the three months ended June 30, 2021 resulting in a cost of goods sold gross margin deficit of $229 thousand. Our product manufacturing capabilities currently have excess capacity to support future growth. Research and development expenses were $910 thousand for the three months ended June 30, 2021. Selling, general and administrative expenses, which include public company costs and non-cash expenses of $620 thousand, were $3.7 million for the three months ended June 30, 2021.

 

While the Company executes its drug development strategy for long-term growth, the Company currently generates revenue from its vivoPharm and StemoniX subsidiaries. On a pro forma basis, assuming the Merger occurred on January 1, 2020, revenues for the three and six-month ended June 30, 2021 were $1.9 million and $3.8 million, respectively, as compared with $1.5 million and $3.1 million for the respective prior-year periods. On a pro forma basis, revenues increased by 26% and 21% in the current-year three and six-month periods as compared with the same prior-year periods.

 

1Pro forma information gives effect to the Merger between Cancer Genetics, Inc. and StemoniX, Inc. as if the Merger had occurred as of January 1, 2020. The pro forma information is presented solely for informational purposes and is not necessarily indicative of the combined results of operations or financial position that might have been achieved for the periods or dates indicated, nor is it necessarily indicative of the future results of the Company. 

 

   
 

 

Vyant Bio’s Conference Call and Webcast and Information

 

Vyant Bio’s management will host a conference call on Monday, August 16, 2021 at 4:30pm ET to discuss the Second Quarter 2021 results and provide strategic business updates, as well as answer questions. Event information is below:

 

Event: Investor Conference Call and Webcast for Second Quarter 2021
Date: Monday, August 16, 2021
Time: 4:30pm ET
Dial In: Toll Free: +1.844.369.8774
Webcast:  https://www.webcaster4.com/Webcast/Page/2756/42335

 

The event will be recorded and archived. Replay information is below:

 

Conference Call Replay Information:

Toll Free:  +1.877.481.4010 PIN: 42335

 

Webcast Replay Information:

https://ir.vyantbio.com/news-events/ir-calendar

 

ABOUT VYANT BIO, INC.

 

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. Vyant Bio is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related disorders. With leading-edge capabilities in data science, biological and chemical sciences, engineering, and regulatory affairs, Vyant Bio capitalizes on in silico, human cell-derived in vitro disease models, and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients. Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Formerly known as Cancer Genetics, Inc., the Company’s name was changed to Vyant Bio, Inc. in March 2021. Vyant Bio is headquartered in the US, with offices in Europe, and Australia.

 

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to conduct research quickly and economically with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge human iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients.

 

vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

 

For more information, please visit or follow Vyant Bio at:

 

Internet: www.vyantbio.com

 

LinkedIn: https://www.linkedin.com/company/vyant-bio

 

Twitter: @VyantBio

 

   
 

 

Forward Looking Statements:

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

 

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

 

Investor Contact:

 

Jennifer K. Zimmons. Ph.D., MBA

Investor Relations

Zimmons International Communications, Inc.

Email: jzimmons@zimmonsic.com

Phone: +1.917.214.3514

 

 

Source: Vyant Bio, Inc.

 

###

 

   
 

 

Vyant Bio, Inc.

(Formerly Known as Cancer Genetics, Inc.)

Consolidated Balance Sheets

(unaudited)

(Shares and USD in Thousands)

 

   June 30,   December 31, 
   2021   2020 
         
Assets          
Current assets:          
Cash and cash equivalents  $26,485   $792 
Trade accounts and other receivables   1,261    357 
Inventory   407    415 
Patent held for sale   30    -  
Prepaid expenses and other current assets   1,890    223 
Total current assets   30,073    1,787 
Non-current assets:          
Fixed assets, net   1,654    1,031 
Operating lease right-to-use assets, net   1,068    1,095 
Intangible assets, net   9,262    - 
Goodwill   21,703    - 
Long-term prepaid expenses and other assets   1,641    136 
Total non-current assets   35,328    2,262 
Total Assets  $65,401   $4,049 
           
Liabilities, Temporary Equity and Stockholders’ Equity (Deficit)          
Current liabilities:          
Accounts payable  $1,016   $1,300 
Accrued expenses   1,246    162 
Deferred revenue   1,416    92 
Obligations under operating leases, current portion   490    486 
Obligation under finance lease, current portion   31    -  
Other current liabilities   3    9 
Current liabilities of discontinued operations   436    -  
Total current liabilities   4,638    2,049 
Obligations under operating leases, less current portion   576    627 
Obligations under finance leases, less current portion   66    - 
Share-settlement obligation derivative   -    1,690 
Warrant liability   1    - 
Accrued interest   -    277 
Long-term debt   57    6,839 
Total Liabilities   5,338    11,482 
           
Commitments and Contingencies   -    -  
Temporary Equity          
Series A Convertible Preferred stock, $0.0001 par value; 4,700 shares authorized, 0 and 4,612 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively (liquidation value of $0 and $11,732, respectively, as of June 30, 2021 and December 31, 2020)   -    12,356 
Series B Convertible Preferred stock, $0.0001 par value; 4,700 shares authorized, 0 and 3,489 shares issued and outstanding, as of June 30, 2021 and December 31, 2020, respectively (liquidation value of $0 and $15,707, respectively, as of June 30, 2021 and December 31, 2020)   -    16,651 
Series C Convertible Preferred stock, $0.0001 par value; 2,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020 (liquidation value of $0 as of June 30, 2021 and December 31, 2020)   -    - 
Total Temporary Equity   -    29,007 
           
Stockholders’ Equity (Deficit)        
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued   -    - 
Common stock, authorized 100,000 shares, $0.0001 par value, 28,985 and 2,594 shares issued and outstanding as of June 30, 2021, and December 31, 2020, respectively   3    - 
Additional paid-in capital   109,567    1,514 
Accumulated comprehensive loss   (1)   - 
Accumulated deficit   (49,506)   (37,954)
Total Stockholders’ Equity (Deficit)   60,063    (36,440)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $65,401   $4,049 

 

   
 

 

Vyant Bio, Inc.

(Formerly Known as Cancer Genetics, Inc.)

Consolidated Statements of Operations

(Shares and USD in Thousands)

 

                     
   Three months ended June 30   Six months ended June 30 
 

2021

  

2020

  

2021

   2020 
Revenues:                
Service  $1,831   $41   $1,947   $176 
Product   116    58    222    91 
Total revenues   1,947    99    2,169    267 
                     
Operating costs and expenses:                    
Cost of goods sold – service   1,027    38    1,116    170 
Cost of goods sold – product   345    147    741    313 
Research and development   910    593    1,730    1,602 
Selling, general and administrative   3,664    408    4,880    1,241 
Merger related costs   165    -    2,310    - 
Total operating costs and expenses   6,111    1,186    10,777    3,326 
Loss from operations   (4,164)   (1,087)   (8,608)   (3,059)
                     
Other (expense) income:                    
Change in fair value of warrant liability   -    -   214    -
Change in fair value of share-settlement obligation derivative   -    (211)    (250)   (211) 
Loss on debt conversions   -    -    (2,518)   - 
Other income (expense)   (25)   1    (25)   1 
Interest income   3    -    3    - 
Interest expense   -    (36)   (368)   (37)
Total other (expense) income   (22)   (246)   (2,944)   (247)
Loss before income taxes   (4,186)   (1,333)   (11,552)   (3,306)
Income tax expense (benefit)   -    -    -    - 
Net loss   $(4,186)  $(1,333)   $(11,552)  $(3,306)
                     
Net loss per common share:                    
Net loss per share attributable to common stock - Basic and Diluted  $

(0.14

)  $

(0.54

)  $

(0.72

)  $(1.34)
Weighted average shares outstanding:                    
Weighted average common shares outstanding - Basic and Diluted   28,985    2,468    16,156    2,464 

 

   
 

 

Vyant Bio, Inc.

(Formerly Known as Cancer Genetics, Inc.)

Consolidated Statements of Cash Flows

(unaudited)

(USD in Thousands)

 

          
   Six months ended June 30, 
   2021    2020 
          
Cash Flows from Operating Activities:            
Net loss  $ (11,552 )  $(3,306)
Reconciliation of net loss to net cash used in operating activities:            
Stock-based compensation   

728

     133 
Amortization of operating lease right-of-use assets    135     244 
Depreciation and amortization expense    567     287 
Change in fair value of share-settlement obligation derivative    250     211 
Change in fair value of warrant liability    (214 )   - 
Change in fair value of 2020 Convertible Note with fair value election   

4

     - 
Accretion of debt discount    173     13 
Loss on conversion of debt    2,518     - 
PPP loan forgiveness    -     (649)
Loss on equipment    6     29 
Changes in operating assets and liabilities, net of impacts of business combination:            
Trade accounts and other receivables    (34 )   (54)
Inventory    8     (50)
Prepaid expenses and other current assets    (1,208 )   151 
Accounts payable    (1,081 )   459 
PPP loan proceeds    -     730 
Obligations under operating leases    (162 )   (247)
Accrued expenses and other current liabilities    (808 )   12 
Net cash used in operating activities    (10,670)     (2,037)
             
Cash Flows from Investing Activities:         
Purchase of equipment    (520 )   - 
Proceeds from sale of equipment   

-

     17 
Cash acquired from acquisition    30,163     - 
Net cash provided by investing activities    29,643     17 
             
Cash Flows from Financing Activities:            
EIDL loan proceeds    -     67 
Issuance of common stock    4     23 
Issuance of Series B Preferred stock, net of issuance costs    -     1,250 
Issuance of Series C Preferred stock, net of issuance costs    1,786     - 
2020 Convertible Note proceeds    5,022     332 
Principal payments on long-term debt    (82 )   - 
Proceeds from related party notes    -    80 
Principal payments on obligations under finance leases    (10 )   (37)
Net cash provided by financing activities    6,720     1,715 
Net increase (decrease) in cash and cash equivalents    25,693     (305)
Cash and cash equivalents, beginning of the period    792     315 
Total cash and cash equivalents, end of period  $ 26,485    $10
Supplemental disclosure of cash flow information:            
Cash paid for interest  $ -    $7 
Cash paid for income taxes    -     - 
Non-cash investing activities:            
Fair value of non-cash merger consideration  $ 59,920    $-
Equipment purchases in accounts payable    37     - 
Right-of-use assets obtained in exchange for new operating lease liabilities    83     - 
Non-cash financing activities:          
Conversion of Preferred Stock to Common Stock upon Merger  $ 30,793    $-
Conversion of 2020 Convertible Notes and accrued interest to Common Stock upon Merger    16,190     - 
Exchange of Series B Preferred stock for 2020 Convertible Notes    -     2,569 
Reclass warrant liability to equity upon Merger    421     - 

 

   
 

 

Pro forma information gives effect to the Merger between Cancer Genetics, Inc. and StemoniX, Inc. as if the Merger had occurred as of January 1, 2020. The pro forma information is presented solely for informational purposes and is not necessarily indicative of the combined results of operations or financial position that might have been achieved for the periods or dates indicated, nor is it necessarily indicative of the future results of the Company.

 

  

For the three months

ended June, 30

  

For the six months

ended June 30,

 
   2021   2020   2021   2020 
Total revenues  $1,947   $1,545   $3,788   $3,139 
Net loss   (4,021)   (2,689)   (5,560)   (5,799)
Pro forma loss per common share, basic and diluted   (0.14)   (0.09)   (0.19)   (0.20)
Pro forma weighted average number of common shares basic and diluted   28,985,924    28,830,441    28,973,370    28,826,652 

 

   

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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vynt-20210816.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 vynt-20210816_def.xml XBRL DEFINITION FILE EX-101.LAB 6 vynt-20210816_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 vynt-20210816_pre.xml XBRL PRESENTATION FILE XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001349929 2021-08-16 2021-08-16 iso4217:USD shares iso4217:USD shares 0001349929 false 8-K 2021-08-16 VYANT BIO, INC. DE 001-35817 04-3462475 2 Executive Campus 2370 State Route 70 Suite 310 Cherry Hill NJ 08002 (201) 479-8126 false false false false false Common Stock VYNT NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 16, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 16, 2021
Entity File Number 001-35817
Entity Registrant Name VYANT BIO, INC.
Entity Central Index Key 0001349929
Entity Tax Identification Number 04-3462475
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Executive Campus
Entity Address, Address Line Two 2370 State Route 70
Entity Address, Address Line Three Suite 310
Entity Address, City or Town Cherry Hill
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08002
City Area Code (201)
Local Phone Number 479-8126
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol VYNT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vyantbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm vynt-20210816.xsd vynt-20210816_lab.xml vynt-20210816_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "vynt-20210816_lab.xml" ] }, "presentationLink": { "local": [ "vynt-20210816_pre.xml" ] }, "schema": { "local": [ "vynt-20210816.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VYNT", "nsuri": "http://vyantbio.com/20210816", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-16to2021-08-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vyantbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-16to2021-08-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-020130-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-020130-xbrl.zip M4$L#!!0 ( #J $%/Y!\!#*4T $T=! * 97@Y.2TQ+FAT;>U]ZU?: M2MOW=]?R?YC;>^][=:\7+.%LV]WU<-+2JJ!@;?O%%9(!1D."F02%O_Z=0Q+" M25"3$'3V\_1NE9"9:ZYK?G.=Y\NW]MGIU_V]+]]JI2KY&]#_OK3K[=/:UR\? M^=_DTX_.QU_*C>IOT&K_/JW]>] U=.L3D%)#"[31 &)P#A_ I3&0]03_10*T MH(FZ!^2+Y*O-YW[O,QC(9@_I2\7'<.RC('S.PL^6DE90SW]$U"@ M;D'SX.N7X\9YVS]>LBL/D#;^M&Y$]BQ&$\@G2-Y4_OH_O8.'G[]\+),5H>\E M?S5?21*;^O3/+!$FZO6M@&FH/?91!UG[>T='AU*@I+Q![FR;I)]C62>L*B,# M7,*A85J8/*T8N@HN;-DDXX%T*BV1S["MD<]D\D'3-$9()0.U+%.V8 \IH&QC MI$.,P=50);_";VJ)HMZ3MS:V4'<<,!4>L_;WOI%-K]&-'RR?MD#4:M:T2^73 M&JC43D^;I6JU?G[R[T'J@/W<:I8J[L_.-!Z0:O7I:U-_\W%>()Z+PDEFV+Y\ M_F*.H&DA1=;]R"$L=YI!^0 _9ZM?7O2?-7Q08#__WWZ-\ MX>BSQ[V73C!D4;N$"D0CJ#I*RX;_R3I &-M0!5 A2R-_.)_FGIO M&Y^_U+_2S0C:?=.P>_VA;8'&D'$?E#"6Q\#H@F\VF2$X0X_D:Q6H::!I#&U- MMI"A/V\ZK6$?F@92R:ZO?_V?R28 .F-@]2&XTI%%WM^R*'J[PJ> M8FB:W#%,!CMD3:T^:)BJ;&! -4>Z;2DTR2:2$Z"N*X>$]0 ^0L6V((-!,HD> M?=BLB6(4( MBM*!-;*V4*?0Y:!NJ>Z@WS_/Q7,5]"D:)U6RV.0X 2_D0Y&R#(-"JH$UC%] MKSR2+=D$BH9TAN4661<-_\]D'[*ET>6.!AD&\IDGGC<3%8Z@9@P'!'P3;%H$ MM2U*.EF6H4$QF1+O6R ,R)J1.?4@A7D"VX@"_- [28@ J;9)WO"\>0Q-Z!'I M@307#YE\B BNC G[%!L33I I$#$R>F\&Q5T(%_ MX#LL&:L8@Z$&GPV<,M#H M9O?V(%9,"'4'(4KU) %$R/ 8Z&3/:@3?!T/#UAVEZQ):%FB-==4T!A",$=14 M^M4A^1'A9X.$R7T'"0(!BF:S-\F@BTQL 9..2:?41Q8Y+X:RCBFX3V6X\YXG%O?#T XPTHL\\;SK8,FW%LDV8[-JZPH89FE!%[)\"%39 A8ZAJ0(: M!#1XTW1^\0!IM/H3T(GY(&L$+V3_]O6_UT],$ M.#_\?I@ );M'9@"DO,/;#R>GC7(-G->N6]?UR]H_X'^Z2D3G,_AR]=734GG MXLO'JZ]>@,"GP;*?$VZ\EGKC9'WLA@_ AW,9J_+]I_V]G[_/V_]07SR 1('L MT>.DIQD=ZA>?B6 R3QMY!=%&,0]J$(T9J=1CWQW3;V$BX1H[M;@'SSO(9KSY MU.2F9QG+>#')*$3?'1DVT5CQ&%MP #Y4SEO_\'BJXW5/FE!C'C]'3\6'H&VH M,IF)1RXPG10@M"(-:!H08L>JF_5C\ZP?:JK+A$"]"TUZG._O*906K/2A:M.H M-SUULY\R*3 \'!R"6OOP[8GESH"&(^?7A'=]F5A/LM)'D%II,I4WHF6I M1,B /"!KR/2M@4$U+WM 64_5,>[6/4H!(E@8$/%0()%CH@[UN8(%?<+6,:D0 MT3\*=W*[C] -!,W]O0>JO>ED*(5.P&*?0>XO/I--I<]D\M#W1K*ER*L&R*)B MSK:(K&/J:),3NO#N(^:D5>2AWB,YH(;X-'BCYS";6R/*9RIU!J42H^R0Q> &C99%\_ZMB UO6D&A4+C>0C3 M[Y*M*/M^P29*AB0[E1G!BF$/Z5YDECA=DYFITW=! CB6;ZL/"0#H/&6#VOC4 MRC8>^"QX3)>[ *G#<$@0AJXW 4)-,QX E16" .33!\.\(W_W((4Q^@LG8DMG MY^CP -M#(I8$(V:@CC[A'=\V@[Z.C30JDJ9!(,C:WQNB(=0(@73Z3IA@!BQ9 MS("R:<8SX!N:"C$#4=ODE@*/9W+' 6>U3*20_)L[,&C.CJT/H$6^ E5\Z/!R M=[?],M0B!/PGF03'-/SS"32)#'\F+[BW*;23+X)DTDGB_E*M_W2G,:>*YZD. MUV'KZ/VNK!$8!M)ACI"�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end